Acute and chronic systemic administration of morphine is known to suppress immune function; however, the effect of chronic intrathecal (IT) morphine on immune function in inflammatory-induced pain is still unclear. This study examined the effects on the immune system of IT morphine in rats with formalin-induced pain. Lumbar IT catheters were implanted in rats and saline or 2.5, 5.0 or 10.0 µg/h morphine were administered for 7 days. On the last day, formalin-induced inflammatory pain was induced in rat hind paws and pain intensity was assessed. Rat spleens were then harvested for immune function assay. The IT morphine induced a dose-dependent analgesic effect and lactic acid dehydrogenase release assay showed dose-dependent suppression of natural killer cell activity. Concanavalin-A-induced splenocyte proliferation assay showed IT morphine to suppress T lymphocyte function in a dose-dependent manner. Flow cytometry showed IT morphine significantly to decrease T lymphocyte function and the percentages of T lymphocyte subsets in a dose-dependent manner. Hence, in inflammatory-induced pain IT morphine was found to suppress immune function. Chronic IT morphine should be used cautiously to treat chronic pain in immunocompromised cases.
Introduction
As a central opioid analgesic, morphine is extensively used in clinics to treat various types of pain. Since the early clinical reports of increased susceptibility to infectious diseases among opioid users, 1,2 morphine has been acknowledged to produce a number of immunosuppressive effects in the presence or absence of pain. Systemic administration of a clinical analgesic dose of morphine has been reported to induce immune suppression, including decreasing natural killer (NK) cell-mediated cytotoxicity, 3, 4 inhibiting T cell function and changing the ratio of T cell subsets. 5, 6 Systemic morphine administration has also been shown to suppress in vitro mitogen-induced lymphocyte proliferation in pain-free mice and rats. 7, 8 Administration of morphine into the epidural and intrathecal (IT) space is carried out in clinics for both post-operative and cancer pain management. Compared with Intrathecal morphine suppresses immune function systemic administration, however, IT administration of morphine could provide long-term analgesia, have little effect on somaesthesia, motion and the sympathetic nervous system, and be stable on the cardiovascular system. 9, 10 So, although extensive studies have demonstrated that systemic administration of morphine has an immunosuppressive effect, few studies have investigated the effects of IT morphine treatment on immune function in a state of pain.
Inflammatory-induced pain is one of the most frequent clinical signs of inflammation and can be induced by different insults, such as traumatic injury and chemicals. As inflammation develops, spontaneous pain often evolves and can result in hyperalgesia (increased pain on stimulation) and allodynia (a lowered pain threshold). 11 Clinically, chronic morphine treatment has proved to be effective in the control of chronic inflammatory pain.
To our knowledge, the impact of chronic IT morphine on immune function in an inflammatory-induced pain state has not been reported previously. The present study aimed to investigate this in an IT catheterized rat model in which inflammatory pain was induced.
Subjects and methods
Experimental procedures conformed to guidelines established by the Council of the Chinese Physiological Society and were approved by the Animal Care Committee of the Central South University, Changsha, China. The study adhered to the Ethical Guidelines of the International Association for the Study of Pain. 12
ANIMALS
Male Sprague-Dawley rats (250 -300 g) were purchased from the Animal Centre of Shanghai Academy of Science, China. All animals were housed in cages at a controlled temperature of 20 ± 0.5°C and were maintained on a 12-h light-dark cycle with free access to food and water. After their arrival in the laboratory the rats were allowed to acclimatize for 1 week before participation in the study.
SURGERY
The surgical procedure has been described previously. 13 Rats were anaesthetized with 10% chloral hydrate 300 -350 mg/kg body weight and their skin was shaved and sterilized. A 2 cm long midline incision was made on the occiput. Superficial and deep neck muscles were separated to give a clear view of the atlanto-occipital membrane. An 18-gauge needle tip was used to make a small hole in the middle of the membrane until a leak of clear cerebrospinal fluid was observed. With the animal's neck flexed, a microspinal catheter (inner diameter 0.12 mm, outer diameter 0.35 mm) was inserted into the lumbar subarachnoid space and gently advanced caudad 8.5 cm to reach the lumbosacral enlargement. The muscle and skin wounds were closed and the proximal end of the catheter was then tunnelled subcutaneously to exit near the top of the head. Natrium penicillin (North China Pharmaceutical Group, Hebei, China) 30 000 U was given subcutaneously to prevent infection. Rats were housed individually to minimize the risk of catheter disruption.
After a recovery period of 1 week, the rats were anaesthetized with chloral hydrate and an osmotic mini-pump (Alzet ® 2001, Alza Corp., Mountain View, CA, USA) filled with either test drug or saline was implanted subcutaneously between the scapulae. The mini-pump was connected tightly to the IT catheter using a polyurethane catheter (inner diameter approximately 0.36 mm). 
FORMALIN TEST
The formalin test was carried out as described previously by Dubuisson and Dennis. 14 Using a microsyringe with a 26gauge needle, 50 µl of 5% formalin was subcutaneously injected into the dorsal surface of the right hind paw and each rat was immediately placed into an observation chamber.
In order to assess the antinociceptive effect of morphine, the pain intensity score (PIS) was recorded by visual observation at intervals of 5 min for a total of 60 min following formalin injection.
The formalin-induced inflammatory pain was divided into three grades as follows: grade 1, the injected paw was only lightly placed on the ground and there was an accompanying limp; grade 2, the injected paw was elevated and was not placed on the ground; and grade 3, the injected paw exhibited spontaneous flinches/shakes. For each 5-min assessment period the PIS was calculated by multiplying the amount of time spent in each grade by its grade number, adding the results for the three grades together and dividing the result by the total observation time (300 s), as follows:
where T 1, T 2 and T 3 are the amounts of time in seconds spent in each of grades 1, 2 and 3, respectively.
The animals were sacrificed immediately following the 1-h nociceptive assessment.
PREPARATION OF SPLEEN CELLS
After sacrifice, the rat spleens were immediately removed aseptically and teased onto steel mesh that was immersed in D-Hanks solution in a plastic dish. Spleens were separated into a single-cell suspension. Briefly, the cells that passed through the mesh were washed twice with D-Hanks solution, the erythrocytes were lysed with double-distilled water and 1.8% sodium chloride was used to balance osmotic pressure. The cells were then suspended in RPMI-1640 (GIBCO ® ; Invitrogen™, Carlsbad, CA, USA) with 10% fetal bovine serum (Evergreen, Hangzhou, China) containing 2 mM glutamine, 100 IU/ml penicillin G and 100 µg/ml streptomycin at a concentration of 5 × 10 6 cells/ml. Cells were counted on a Coulter Counter ® Series Z1™ (Beckman Coulter, Krefeld, Germany) and cell viability was determined by the trypan blue exclusion test. The spleen index was also calculated as follows: spleen index = splenic weight body weight.
LYMPHOCYTE PROLIFERATION ASSAY
The response of spleen cells to concanavalin A (ConA) stimulation was assessed as previously described. 15 
CYTOTOXICITY ASSAY FOR NK CELL ACTIVITY
A modified lactic acid dehydrogenase (LDH) release assay was used in a 22-h standard cytotoxicity assay as described previously. 16 All cells were transferred into RPMI-1640 medium without phenol red. Effector cells at a range of concentrations were incubated with 1 × 10 4 target YAC-1 cells (NK-sensitive cell line) in 96-well round-bottomed microtitre plates (Nunc™). Effector -target cell ratios of 5:1, 10:1, 25:1 and 50:1 were achieved in each well by diluting effector cells and target cells with culture medium to a final volume of 100 µl. After incubation for 22 h, the plates were centrifuged at 800 rpm (250 g) for 10 min. Aliquots of cell-free supernatant (100 µl) were transferred to flatbottomed microtitre plates (Nunc™) and these were read at 490 nm on a multiscan photometer (Elx 800UV; Bio-Tek ® , Winooski, VT, USA). The LDH activity in these supernatants was assayed using a LDH cytotoxicity assay kit (K311-400; BioVision, Mountain View, CA, USA), using 100 µl of reaction mixture added to each well followed by incubation for 30 min at room temperature. The percentage of specific lysis was calculated using the following formula:
where 'test' is the experimental LDH release resulting from co-culture of effector and target cells, 'spontaneous' is the LDH release resulting from target cells added to culture medium alone, and 'maximal' is the LDH release which was achieved by the addition of 100 µl of 2% Triton ® X-100 (Sigma-Aldrich, St Louis, MO, USA) to 100 µl of target cell suspension. All groups were tested in triplicate. 
IMMUNOFLUORESCENT-ANTIBODY LABELLING OF CELLS -THREE-COLOUR FLOW CYTOMETRY
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was performed using a flow cytometer (Beckman Coulter, Fullerton, CA, USA) equipped with a 15 mW argon-ion laser with excitation capabilities at 488 nm. Fluorescence detector 1 (FL1) was set at a 530 nm bandpass filter to measure FITC (green fluorescence), fluorescence detector 2 (FL2) was set at 585 nm to measure PE (orange fluorescence) and fluorescence detector 3 (FL3) was set at 667 nm to measure PE-Cy5 (red fluorescence). To analyse the data, forward angle light-scatter versus single angle light-scatter histograms were used to gate on live cells, and fluorescence profiles of cells within the live population were examined. Data were collected and analysed using Expo32v1.2 analysis software (Beckman Coulter, Mississauga, Ontario, Canada).
STATISTICAL ANALYSIS
Data are presented as mean ± SD. The time-response data for nociceptive behaviour induced by formalin are presented as PIS. Statistical analysis of PIS data was performed by two-way analysis of variance (ANOVA), followed by post hoc Tukey's test for multiple comparisons. Statistical analysis of the data for ConA-induced cell proliferation, NK cell activity and flow cytometry was performed by one-way ANOVA. P-values < 0.05 were considered to be statistically significant.
Results
FORMALIN TEST
Two distinct phases were observed: phase 1, during the 0 -6 min interval after injection, and phase 2, beginning approximately 10 min after injection. Compared with salinetreated rats, morphine-treated rats exhibited quieter behaviour and crouched in the corner of the glass jar. All three doses of IT morphine significantly reduced PIS following formalin injection (P < 0.01) ( Fig. 1 ). There was no significant difference in PIS between the morphine-treated groups. 
CELL VIABILITY AND SPLEEN INDEX
Spleen cell viability determined by the trypan blue exclusion test was > 95% in all groups. The spleen index in the salinetreated group was 5.75 mg/g whereas, by comparison, the 2.5, 5.0 and 10.0 µg/h IT morphine treatments resulted in a significant decrease (P < 0.05, P < 0.01 and P < 0.01, respectively) ( Fig. 2) , with the greatest reduction seen in the 10.0 µg/h IT morphine-treated group. There were no significant differences between the morphine-treated groups.
MITOGEN-INDUCED LYMPHOCYTE PROLIFERATION
The effect of morphine on mitogen-induced lymphocyte proliferation was studied using ConA and, in all groups, ConA resulted in lymphocyte proliferation as measured by 3 H-TDR incorporation, with 5.0 µg/ml ConA being the best stimulating concentration at all morphine concentrations tested (Fig. 3) .
Chronic IT morphine dramatically decreased
ConA-induced T lymphocyte proliferation in a dose-dependent manner (P < 0.05). Compared with the 2.5 and 5.0 µg/h morphine treatments the greatest effect was seen in the 10.0 µg/h treatment (P < 0.01).
SPLENIC NK CELL ACTIVITY
The NK cell activity, measured by the specific percentage of lysed cells calculated from the LDH release assay, showed chronic IT morphine significantly to suppress LDH release (reduce specific lysis) in a dosedependent manner, reaching its greatest effect at the 10 µg/h dose (P < 0.01) ( Fig. 4 ). No statistical significance was observed between the experimental groups.
T LYMPHOCYTE AND NK CELL PHENOTYPES
Chronic IT morphine treatment significantly decreased the percentages of CD3 + , CD3 + CD4 + , CD3 + CD8 + and CD161 + T lymphocyte subsets compared with the saline treatment with the greatest effect occurring at the 10.0 µg/h morphine dose (P < 0.01) (Fig. 5 ). The 10.0 µg/h dose of morphine decreased percentage values by more than two-fold compared with the saline-treated group (P < 0.01) and by 50% compared with the 2.5 µg/h morphine-treated group (P < 0.05). There was no effect of 2.5 or 5.0 µg/ml intrathecal morphine on the CD3 + CD8 + T lymphocyte subsets compared with the saline treatment.
Discussion
The present study has demonstrated that formalin-induced pain can be relieved by IT morphine. The widely known rat model for inflammatory pain was used of hind paw injection of formalin to cause tonic pain simulating clinical chronic pain. Formalin injection causes two periods of flinching responses: an acute nociceptive response lasting for the first 5 min (early phase) and a late flinching response occurring after 10 -15 min and peaking 40 -50 min after injection. 14 In the present study, all three doses of morphine dramatically reduced the PIS of biphasic nociceptive behavioural responses and achieved similar analgesic effects. An early study demonstrated that the infusion of 200 µg of morphine through an IT catheter produced an analgesic effect in patients with hip arthroplasty. 17 In the present study, the analgesic doses of morphine that were used (2.5 -10.0 µg/h) correlate with clinical doses of morphine that are used in pain management. The lowest dose of morphine used in the present study was much lower than the analgesic dose of morphine administered systemically (5 -10 mg/kg) in animal studies. 18 Natural killer cells, a subset of lymphocytes, play an important role in the immune defence system against viral and bacterial infection, and mediate spontaneous cytotoxicity against tumour cells. 19, 20 Extensive studies in humans and animals have shown that morphine inhibits 633 W Zou, Q Guo, E Wang et al. 2 More recent studies have demonstrated that intravenous morphine reduces both NK cell activity and antibody-dependent cellular cytotoxicity (ADCC) in human volunteers. 4 Acute or chronic morphine treatment administered by subcutaneous injection has also been reported to suppress splenic NK cell activity in rats. 21 All these studies are strongly suggestive of morphine being able to reduce NK cell and ADCC activities in vivo. In the present study, the splenic NK cell activity that occurs in an inflammatory pain state was significantly inhibited by IT morphine in a dose-dependent manner. Even the lowest dose of 2.5 µg/h IT morphine produced evident suppression of NK cell activity.
Intrathecal morphine suppresses immune function
There is considerable evidence showing that morphine given in vivo modulates T cell function. Early studies showed that systemic morphine administration significantly depressed T cell function in neuropathic or post-operative pain. 22, 23 Alexander et al. 24 suggested that the therapeutic administration of exogenous opiates appears to contribute to the development of post-burn immune dysfunction.
In agreement with earlier studies, the present study also showed that even our lowest dose of 2.5 µg/h of morphine inhibited T cell function, as indicated by mitogen (ConA)induced lymphocyte proliferation measured by 3 H-TDR incorporation, a common method of measuring T cell function. Collectively, analgesic doses of morphine, given by either systemic or IT administration, could suppress T cell function in various types of pain state.
Early animal studies demonstrated that systemic morphine administration alters the ratio of T helper/inducer (CD4 + ) and T suppressor/cytotoxic (CD8 + ) T lymphocyte subsets. 25, 26 On the other hand, equianalgesic doses of IT morphine were reported not to change the number of leucocytes or the phenotypic expression of cell surface markers of T cell subsets in rats. 27 In the present study, however, IT morphine decreased the number of splenic leucocytes, including T cell subsets and NK cells (CD161 + ). This discrepancy in the effect of IT morphine on the immune function between our study and the earlier report may be due to the period of administration. In the present study IT morphine was administered for 1 week, whereas administration lasted for only 24 h in the earlier study. The present study in combination with earlier studies suggests that it is chronic, not short-term, IT morphine that reduces the number of leucocyte subsets and changes leucocyte distribution.
The mechanism of the immunosuppressive effect of morphine is not completely understood. Shavit et al. 28 suggested that the inhibition of NK cells by morphine is centrally mediated because peripherally administered N-methylmorphine, which cannot pass the blood-brain barrier, was ineffective on NK cells. These studies were confirmed and extended by Weber and Pert, 29 who found that morphine acted to depress NK cell activity via the periaqueductal grey region of rat brain. The effect of morphine on T cells was also suggested to be mediated by the opioid receptors in the brain. 30 Activation of the hypothalamic-pituitary-adrenal axis and the production of glucocorticoids or activation of the sympathetic nervous system are two major efferent mechanisms through which morphine centrally suppresses the immune system. 31, 32 In addition, the suppressive effect of morphine on T lymphocyte proliferation was suggested not to be mediated by glucocorticoids or pituitary factors, as neither adrenalectomy nor hypophysectomy abrogated suppression. 33 W Zou, Q Guo, E Wang et al.
In the present study, IT morphine suppressed the ConA-induced T lymphocyte proliferation, suggesting that a spinal mechanism might be involved in the suppressive effect of morphine on mitogen-induced T cell proliferation. The immunosuppressive effect of IT morphine could be due either to a direct action of morphine on the opioid receptor in the blood-brain barrier or an indirect action on the opioid receptor of peri-immune cells in blood circulating through the subarachnoid space venous plexus. The mechanism by which IT morphine suppresses the immune function remains to be determined.
The observation in the present study that chronic IT morphine suppressed immune function suggests that chronic IT morphine should be used cautiously for chronic inflammatory pain. Long-term IT morphine increases the risk for a multitude of infectious diseases, most notably HIV infection and associated infectious agents. Immunomodulatory drugs may overcome such deleterious effects and spare the beneficial effect of morphine during longterm treatment of chronic pain. It can be anticipated that further understanding of the neuroimmunological mechanisms underlying immunomodulatory drugs, morphine and their interactions will advance and improve clinical management of opioid therapy in the management of chronic pain syndromes.
In summary, the present study using an inflammatory pain model, has shown that IT morphine administration may suppress immune function by changing both the activities and percentage of immune cells, and suggests that a spinal mechanism may be involved in morphine-induced immunosuppression. We suggest that IT morphine for alleviating chronic inflammatory pain should be used cautiously in immunocompromised cases.
